Falciparum nomenclature.

L. Bruce-Chwatt

DOI: https://doi.org/10.1016/0169-4758(87)90153-0

Parasitology Today

Abstract:

What problem does this paper attempt to address?

OSU-T315 Overcomes Immunosuppression in Triple-Negative Breast Cancer by Targeting the ILK/NF-κB Signaling Pathway to Enhance Immunotherapeutic Efficacy

Yi Wang,Yuenong Qin,Chunyu Wu,Jiajing Chen,Yang Zhang,Yueqiang Chen,Xiaohong Xie,Xiufei Gao,Chenping Sun,Sheng Liu

DOI: https://doi.org/10.1016/j.intimp.2024.113530

IF: 5.714

2024-01-01

International Immunopharmacology

Abstract:Triple negative breast cancer (TNBC) is an aggressive and immunogenic subtype of breast cancer. The absence of biomarker has given immune checkpoint inhibitors (ICIs) a broad prospect in this type of breast cancer. The infiltration of regulatory T cells (Tregs) expressing transcription factor forkhead box P3 (Foxp3) in the tumor microenvironment (TME) is the key factor leading to ICIs resistance. Therefore, elimination of tumor antigen-specific Tregs may be an important aspect of improving ICIs efficacy. In this study, it based on the Gene Expression Omnibus and The Cancer Genome Atlas database, along with in vivo and in vitro experimental models, to verified that the high expression of integrin-linked kinase (ILK) in TNBC is the key differential factor leading to the high infiltration of Foxp3+-Tregs in the TME. Then, we selected ILK-specific inhibitor, OSU-T315, to intervene in vitro and vivo. Importantly, we found that OSU-T315 blocked the secretion of CCL17/CCL22 in tumor cells by inhibiting the ILK/NF-κB pathway, resulting in the apoptosis of Foxp3+-Tregs and decreased programmed cell death-1 (PD-1) expression. Therefore, our findings indicate a novel mechanism of OSU-T315 with potential therapeutic application in TNBC.
Abstract P2-04-27: CTLA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer

P. Agarwal,Erika J. Crosby,Gangjun Lei,X. Yang,H. Lyerly,Z. Hartman,C.-X. Liu,Tian-Li Wang,Junyuan Wei

DOI: https://doi.org/10.1158/1538-7445.SABCS16-P2-04-27

2017-02-15

Abstract:Despite a lack of unifying drivers in Triple-Negative Breast Cancer (TNBC), our lab and others have uncovered that these cancers have elevated expression of inflammatory genes and immunosuppressive molecules (i.e. PD-L1), as well as elevated numbers of infiltrating immune cells (including CD8+ T-cells and Foxp3+ T-regulatory cells) which suggests the therapeutic potential for single and combinations of checkpoint blockade antibodies. While early trials with PD-1 inhibitors have been encouraging for TNBC, only a fraction of treated patients respond to this therapy. To test and define the mechanisms that govern responses, we explored the utility and mechanistic basis of both PD-1 and CTLA-4 inhibition in generating tumor-specific immunity in an established murine model of TNBC. Consistent with patient samples, we found TNBC tumors from our model exhibited elevated PD-1+ expressing CD8+ T-cell infiltrates, Foxp3+ T-regulatory cell infiltrates (~66% of CD4+ TILs), as well as highly elevated tumor cell expression of PD-L1. We also found that while TNBC cells were easily killed by T-cell in vitro, TNBC tumors were highly immuno-suppressive and resistant to antigen-specific T-cell attack in vivo, even after adoptive transfer of up to 5x10E6 tumor-specific T-cells. However, we found that both CTLA-4 and PD-1 antibodies could curtail this immunosuppression to different degrees and through alternate mechanisms. Specifically, we found that CTLA-4 antibody mediated anti-tumor immunity through the elimination and blockade of Foxp3+ T-regulatory cells in the tumor microenvironment, which allow for potent T-cell expansion. Conversely, PD-1 antibodies elicited anti-tumor immunity through blockade of PDL1/PD1 signaling between tumor cells and T-cells in the TNBC tumor microenvironment that allowed for a more modest expansion of individually tailored T-cell specific clones in vivo. Strikingly, the combination of these antibodies and their alternate mechanisms of action resulted in greatly enhanced anti-tumor responses and led to regression of ~80% of tumors. This was accompanied by an augmented infiltration of T-cells into the tumor microenvironment and significantly enhanced systemic tumor-specific T-cell responses, which appear to be emergent properties of dual CTLA-4/PD-1 antibody treatment. However, we found that these treatments did not expand a common tumor-specific T-cell clone, despite adoptive transfer of identical tumor-specific immunodominant T-cells into mice after tumor implantation. Thus, despite our use of a highly homogeneous model utilizing genetically identical mice implanted with an identical tumor line bearing a unique tumor antigen under identical conditions, the tumor-specific T-cell responses were highly unique for each individual tumor. Collectively, our study suggest that dual blockade could be an effective therapeutic clinical strategy against TNBC and further suggest the utility of monitoring systemic immune response and TCR expansion of TILs as the most useful correlates in clinical studies utilizing CTLA-4 and PD-1 antibodies. Citation Format: Hartman ZC, Crosby EJ, Wei J-P, Yang X-Y, Lei G-J, Wang T, Liu C-X, Agarwal P, Morse MS, Lyerly HK. CTLA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-04-27.

Medicine,Biology
[The effect of nitric oxide on electroacupuncture analgesia in central nervous system of rats].

B. Bai,Wenyao Liu,Hong Wang

2002-02-01

Abstract:
Tumor‐infiltrating lymphocyte transfusion in a patient with treatment refractory triple negative breast cancer

Arielle Jacover,Yonaton Zarbiv,Keidar Haran Tal,Shira Klein,Shani Breuer,Ronen Durst,Batia Avni,Sigal Grisariu,Polina Stepensky,Michal Lotem,Ofra Maimon,Tamar Yablonski‐Peretz,Tal Kiedar Haran

DOI: https://doi.org/10.1002/cnr2.1894

2023-09-26

Cancer Reports

Abstract:Abstract Background Triple negative breast cancer (TNBC) is an aggressive form of breast cancer that is treated with chemotherapy. Recently, programmed death 1 (PD1) inhibition, as well as antibody‐drug conjugates, have been added to the available treatment regimen, yet metastatic disease is fatal. Adoptive cell therapy (ACT) using tumor infiltrating lymphocytes (TILs) has been well described in melanoma, but less data is available on other solid malignancies. Case Herein, we present a case of a 31‐year‐old patient diagnosed with Breast Cancer gene 1 (BRCA1) positive, TNBC. The patient's disease rapidly progressed while under standard treatment protocols. As a result, additional genetic testing of the tumor was carried out and revealed loss of BRCA1 heterozygosity, a double Tumor Protein 53 (TP53) mutation, and MYC amplification. Due to resistance to conventional therapy, an experimental approach was attempted using tumor‐infiltrating lymphocytes in November 2021 at Hadassah University Medical Center. While receiving this treatment, the patient exhibited a reported subjective clinical improvement including a month spent out of the hospital. However, the final result, presumably due to Interleukin 2 (IL‐2) toxicity, was the patient's passing. Conclusion This case is unique and peculiar regarding the treatment modality chosen, due to the extremely refractory disease the patient suffered from. After standard therapies rapidly failed, adoptive cell therapy was attempted with the infusion of TILs. This treatment has been shown effective in melanoma, however, there is an extreme paucity of data on other solid tumors, including TNBC. Although the patient ultimately demised presumably due to treatment side effects, brief clinical benefit was apparent. Further studies are warranted.
Concomitant Expression of CD39, CD69, and CD103 Identifies Antitumor CD8+ T Cells in Breast Cancer Implications for Adoptive Cell Therapy

Grace Ivonne Gattas Lama,Gregory Noél,Francisco Carlos López Márquez,Faviel Francisco González Galarza,Adria Imelda Prieto Hinojosa,Lydia Enith Nava Rivera,Karen Willard-Gallo,Jesús Rafael Arguëllo Astorga

DOI: https://doi.org/10.2174/1389201025666230901094219

Abstract:Background: In cancer, an effective immune response involves the action of several different cell types, among which CD8 T cells play a major role as they can specifically recognize and kill cancer cells via the release of cytotoxic molecules and cytokines, being of major importance for adoptive cell transfer (ACT) of ex vivo expanded tumor-infiltrating lymphocytes (TILs). The inflammation resulting from the tumor growth attracts both activated and bystander T cells. For an effective antitumor response, the T cell must express a specific group of chemokine receptors and integrins which include CD103, CD39, CD69, and CD25. These markers had already been analyzed in various cancers, not including breast cancer and their subsequent subtypes, until now. To analyze, the key receptors on ex vivo expanded tumor-infiltrating lymphocytes in luminal A and luminal B breast cancer (BC) subtypes. Materials and methods: We were successful in expanding TILs ex vivo using a standard TIL culture condition from a cohort study of 15 primary luminal A and luminal B breast cancer patients. Furthermore, we examined the expression of CD103, CD39, CD69, and CD25 biomarkers after the expansion by flow cytometry. Results: We found that the information about the percentage of TILs obtainable after the ex vivo expansion is not associated to nor it is dependent on the heterogeneity of the TIL population before the expansion and does not differ by the molecular subtype (p>0.05). We also found that there is a major population of memory-resident antitumor CD8+CD103+CD39+ and CD8+CD103+ CD69+ TILs present in the stroma after the expansion when compared to CD4 immunosubtypes (p<0.0001). Only the CD8+CD103+CD39+ subpopulation was related to BC subtype (0.0009). Conclusion: Evidence from our study suggests that CD8 TILs present in the stroma of luminal A and luminal B breast cancer patients can be quantified and phenotyped by flow cytometry and be further expanded ex vivo. The immuno-phenotyping of these markers may be targeted to improve the success of immunotherapeutic approaches, such as adoptive cellular therapy (ACT) in patients with BC.
Augmentation of Antitumour Function of Tumour-infiltrating Lymphocytes Against Triple-negative Breast Cancer by PD-1 Blockade

Haiyan Hu,Hongming Song,Haibo Wang,Mingkai Gong,Li Wu,Weihong Cao,Xueqiang Gao,Rongrong Dou,Qiaoyu Chen

DOI: https://doi.org/10.21203/rs.3.rs-805218/v1

2021-08-13

Abstract:Abstract T-cell-based immunotherapy and immune checkpoint blockade have been successfully used to treat several human solid cancers. The present study attempted to investigate the feasibility and efficacy of the antitumour effect of adoptive cell therapy along with programmed cell death protein 1 (PD-1) inhibitor on triple-negative breast cancer (TNBC). We isolated and expanded tumour infiltration lymphocytes (TILs) from TNBC mouse tumour tissues and adoptive TIL transfusion (TILs-ACT) was applied in combination with a PD-1 inhibitor to the TNBC mouse model. The pre- and post-therapy antitumour efficacy, cytokine secretion, and pathological changes were assessed both in vitro and in vivo. TILs exhibited higher IFN-γ and TNF-α secretion than conventional T cells. The TILs-ACT combined with PD-1 inhibitor promoted active T-cell infiltration into the tumour tissue and exerted a strong antitumour effect in an in vivo model. Additionally, the strategy could downregulate the expression of inhibitory marker PD-1 on TILs. Our results suggested that PD-1 blockade regulated T-cell exhaustion which synergised with adoptive TIL transfer immunotherapy, leading to eradication of established TNBC tumours. These findings might be useful in developing a feasible and effective therapeutic approach for TNBC.
Enhancing Efficacy of TCR-engineered CD4 + T Cells Via Coexpression of CD8α

Victoria E Anderson,Sara S Brilha,Anika M Weber,Annette Pachnio,Guy E Wiedermann,Sumaya Dauleh,Tina Ahmed,George R Pope,Laura L Quinn,Roslin Y Docta,Adriano Quattrini,Siobhan Masters,Neil Cartwright,Preetha Viswanathan,Luca Melchiori,Louise V Rice,Alexandra Sevko,Claire Gueguen,Manoj Saini,Barbara Tavano,Rachel J M Abbott,Jonathan D Silk,Bruno Laugel,Joseph P Sanderson,Andrew B Gerry

DOI: https://doi.org/10.1097/CJI.0000000000000456

2023-05-01

Abstract:Adoptive cell therapy with T cells expressing affinity-enhanced T-cell receptors (TCRs) is a promising treatment for solid tumors. Efforts are ongoing to further engineer these T cells to increase the depth and durability of clinical responses and broaden efficacy toward additional indications. In the present study, we investigated one such approach: T cells were transduced with a lentiviral vector to coexpress an affinity-enhanced HLA class I-restricted TCR directed against MAGE-A4 alongside a CD8α coreceptor. We hypothesized that this approach would enhance CD4 + T-cell helper and effector functions, possibly leading to a more potent antitumor response. Activation of transduced CD4 + T cells was measured by detecting CD40 ligand expression on the surface and cytokine and chemokine secretion from CD4 + T cells and dendritic cells cultured with melanoma-associated antigen A4 + tumor cells. In addition, T-cell cytotoxic activity against 3-dimensional tumor spheroids was measured. Our data demonstrated that CD4 + T cells coexpressing the TCR and CD8α coreceptor displayed enhanced responses, including CD40 ligand expression, interferon-gamma secretion, and cytotoxic activity, along with improved dendritic cell activation. Therefore, our study supports the addition of the CD8α coreceptor to HLA class I-restricted TCR-engineered T cells to enhance CD4 + T-cell functions, which may potentially improve the depth and durability of antitumor responses in patients.
Abstract P5-04-28: Targeting TIGIT and PD-1 in triple negative breast cancer

Apurva Kumari Pandey,Joe Marc Chauvin,Adam Brufsky,Ornella Pagliano,Mignane Ka,Carmine Menna,Priscilla McAuliffe,Hassane Zarour

DOI: https://doi.org/10.1158/1538-7445.sabcs19-p5-04-28

2020-02-14

Abstract:Abstract Background: Triple negative breast cancer is aggressive and has poor prognosis. Tumor infiltrating lymphocytes (TILs) have a prognostic value in triple negative breast cancer. Increased TILs are associated with better disease-free survival and overall survival in triple negative breast cancer (TNBC). Newly approved immunotherapy drug for metastatic triple negative breast cancer patients, Atezolizumab, has shown 10 months improvement in overall survival in for PD-L1 positive group in combination with nab-paclitaxel compared to placebo and paclitaxel. Beyond PD-1 inhibitors, there is a need to improve immunotherapy options in TNBC. TIGIT gene expression in triple negative breast cancer is associated with immune function is linked with improved relapse free survival and overall survival. CD155, a high affinity receptor for TIGIT, is expressed on tumor cells including lung and melanoma. We aim to evaluate the role of TIGIT in regulating immune response to TNBC, TIGIT cooperation with PD-1 in impeding T cell responses to TNBC, and expression of TIGIT ligands on TNBC. Methods: Fresh TNBC tumor samples were obtained from 10 untreated patients and were used for single cell suspension and multi parameter flow cytometry. Results: CD8+ and CD4+ TILs in TNBC exhibited higher PD-1 and TIGIT, yet lower CD226 expression as compared to circulating T cells. LAG-3 and TIM3 were expressed at low frequency in CD 8+ and CD 4+ cells. TNBC Tregs display high expression of TIGIT, PD-1, TIM3 but low CD226 expression. TIGIT interacts with CD155 and CD112 with high affinity and both were found to be highly expressed by TNBC tumor cells and APCs. PD-1−TIGIT+ CD8+ TILs are present at high frequency and appear to represent an activated T cell subset. PD-1+Tim-3+TIGIT+ produced less cytokines including interferon gamma, IL-2, and TNF than other CD8+ T cell subsets, representing a dysfunctional T cell subset. Conclusions: TIGIT is highly upregulated by TNBC CD8+ and CD4+ TILs while the TIGIT ligands are highly expressed by tumor cells and APCs in TNBC. In sharp contrast with metastatic melanoma, high frequency PD-1−TIGIT+CD8+ TILs are present in TNBC. Additional studies will investigate the role of dual PD-1/TIGIT blockade in increasing CD8+ TIL function in TNBC. Such data may support the dual PD-1/TIGIT blockade in TNBCs. Citation Format: Apurva Kumari Pandey, Joe Marc Chauvin, Adam Brufsky, Ornella Pagliano, Mignane Ka, Carmine Menna, Priscilla McAuliffe, Hassane Zarour. Targeting TIGIT and PD-1 in triple negative breast cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P5-04-28.
Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells

Roberta Sommaggio,Elisa Cappuzzello,Anna Dalla Pietà,Anna Tosi,Pierangela Palmerini,Debora Carpanese,Lorenzo Nicolè,Antonio Rosato

DOI: https://doi.org/10.1080/2162402X.2020.1777046

2020-06-13

OncoImmunology

Abstract:Cytokine-Induced Killer (CIK) cells share several functional and phenotypical properties of both T and natural killer (NK) cells. They represent an attractive approach for cell-based immunotherapy, as they do not require antigen-specific priming for tumor cell recognition, and can be rapidly expanded in vitro . Their relevant expression of FcγRIIIa (CD16a) can be exploited in combination with clinical-grade monoclonal antibodies (mAbs) to redirect their lytic activity in an antigen-specific manner. Here, we report the efficacy of this combined approach against triple negative breast cancer (TNBC), an aggressive tumor that still requires therapeutic options. Different primitive and metastatic TNBC cancer mouse models were established in NSG mice, either by implanting patient-derived TNBC samples or injecting MDA-MB-231 cells orthotopically or intravenously. The combined treatment consisted in the repeated intratumoral or intravenous injection of CIK cells and cetuximab. Tumor growth and metastasis were monitored by bioluminescence or immunohistochemistry, and survival was recorded. CIK cells plus cetuximab significantly restrained primitive tumor growth in mice, either in patient-derived tumor xenografts or MDA-MB-231 cell line models. Moreover, this approach almost completely abolished metastasis spreading and dramatically improved survival. The antigen-specific mAb favored tumor and metastasis tissue infiltration by CIK cells, and led to an enrichment of the CD16a + subset. Data highlight the potentiality of this novel immunotherapy strategy where a nonspecific cytotoxic cell population can be converted into tumor-specific effectors with clinical-grade antibodies, thus providing not only a therapeutic option for TNBC but also a valid alternative to more complex approaches based on chimeric antigen receptor-engineered cells. ACT, Adoptive Cell Transfer; ADCC, Antibody-Dependent Cell-mediated Cytotoxicity; ADP, Adenosine diphosphate; BLI, Bioluminescence Imaging; CAR, Chimeric Antigen Receptor; CIK, Cytokine Induced Killer cells; CTX, Cetuximab; DMEM, Dulbecco's Modified Eagle Medium; EGFR, Human Epidermal Growth Factor 1; ER, Estrogen; FBS, Fetal Bovine Serum; FFPE, Formalin-Fixed Paraffin-Embedded; GMP, Good Manufacturing Practices; GVHD, Graft Versus Host Disease; HER2, Human Epidermal Growth Factor 2; HRP, Horseradish Peroxidase; IFN-γ, Interferon-γ; IHC, Immunohistochemistry; IL-2, Interleukin-2; ISO, Irrelevant antibody; i.t., intratumoral; i.v., intravenous, mAbs, Monoclonal Antibodies; mIHC, Multiplex Fluorescence Immunohistochemistry; MHC, Major Histocompatibility Complex; NK, Natural Killer; NKG2D, Natural-Killer group 2 member D; NSG, NOD/SCID common γ chain knockout; PARP, Poly ADP-ribose polymerase; PBMCs, Peripheral Blood Mononuclear Cells; PBS, Phosphate-buffered saline; PDX, Patient-derived xenograft; PR, Progesterone; rhIFN-γ, Recombinant Human Interferon-γ; RPMI, Roswell Park Memorial Institute; STR, Short tandem Repeat; TCR, T Cell Receptor; TNBC, Triple Negative Breast Cancer; TSA, Tyramide Signal Amplification

oncology,immunology
Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function

Sarah L Buchan,Lang Dou,Marcus Remer,Steven G Booth,Stuart N Dunn,Chester Lai,Monika Semmrich,Ingrid Teige,Linda Mårtensson,Christine A Penfold,H T Claude Chan,Jane E Willoughby,C Ian Mockridge,Lekh N Dahal,Kirstie L S Cleary,Sonya James,Anne Rogel,Päivi Kannisto,Mats Jernetz,Emily L Williams,Eugene Healy,J Sjef Verbeek,Peter W M Johnson,Björn Frendéus,Mark S Cragg,Martin J Glennie,Juliet C Gray,Aymen Al-Shamkhani,Stephen A Beers

DOI: https://doi.org/10.1016/j.immuni.2018.09.014

IF: 32.4

2018-11-20

Immunity

Abstract:The costimulatory receptor 4-1BB is expressed on activated immune cells, including activated T cells. Antibodies targeting 4-1BB enhance the proliferation and survival of antigen-stimulated T cells in vitro and promote CD8 T cell-dependent anti-tumor immunity in pre-clinical cancer models. We found that T regulatory (Treg) cells infiltrating human or murine tumors expressed high amounts of 4-1BB. Intra-tumoral Treg cells were preferentially depleted by anti-4-1BB mAbs in vivo. Anti-4-1BB mAbs also promoted effector T cell agonism to promote tumor rejection. These distinct mechanisms were competitive and dependent on antibody isotype and FcγR availability. Administration of anti-4-1BB IgG2a, which preferentially depletes Treg cells, followed by either agonistic anti-4-1BB IgG1 or anti-PD-1 mAb augmented anti-tumor responses in multiple solid tumor models. An antibody engineered to optimize both FcγR-dependent Treg cell depleting capacity and FcγR-independent agonism delivered enhanced anti-tumor therapy. These insights into the effector mechanisms of anti-4-1BB mAbs lay the groundwork for translation into the clinic.
Immunotherapy of cancer with 4-1BB

Dass S Vinay,Byoung S Kwon

DOI: https://doi.org/10.1158/1535-7163.MCT-11-0677

Abstract:4-1BB (CD137), a member of the TNF receptor superfamily, is an activation-induced T-cell costimulatory molecule. Signaling via 4-1BB upregulates survival genes, enhances cell division, induces cytokine production, and prevents activation-induced cell death in T cells. The importance of the 4-1BB pathway has been underscored in a number of diseases, including cancer. Growing evidence indicates that anti-4-1BB monoclonal antibodies possess strong antitumor properties, which in turn are the result of their powerful CD8+ T-cell activating, IFN-γ producing, and cytolytic marker-inducing capabilities. In addition, combination therapy of anti-4-1BB with other anticancer agents, such as radiation, has robust tumor-regressing abilities against nonimmunogenic or poorly immunogenic tumors. Furthermore, the adoptive transfer of ex vivo anti-4-1BB-activated CD8+ T cells from previously tumor-treated animals efficiently inhibits progression of tumors in recipient mice that have been inoculated with fresh tumors. In addition, targeting of tumors with variants of 4-1BBL directed against 4-1BB also have potent antitumor effects. Currently, a humanized anti-4-1BB is in clinical trials in patients with solid tumors, including melanoma, renal carcinoma, and ovarian cancer, and so far seems to have a favorable toxicity profile. In this review, we discuss the basis of the therapeutic potential of targeting the 4-1BB-4-1BBL pathway in cancer treatment.
Abstract A22: Deciphering natural killer transcriptional activation in triple-negative breast cancer: A novel opportunity for adoptive cell therapies?

Francesca Reggiani,Benedetta Donati,Moira Ragazzi,Veronica Manicardi,Federica Torricelli,Elisabetta Sauta,Elisa Gasparini,Simonetta Piana,Valentina Sancisi,Alessia Ciarrocchi

DOI: https://doi.org/10.1158/2326-6074.tumimm22-a22

IF: 10.1

2022-12-04

Cancer Immunology Research

Abstract:Triple-Negative Breast Cancer (TNBC) patients that do not respond to neoadjuvant chemotherapy account for 60-70% of all cases and are orphans of therapeutic alternatives after chemotherapy failure. Despite the great progress that has been made in the application of immune-based strategies, clinical opportunities for TNBC patients are still lacking. We aimed to investigate the molecular mechanisms leading to the activation of the TNBC immunological microenvironment, thus providing novel clues for the design and development of immune-based therapeutic approaches and adoptive immune cell therapies for TNBC patients. We analyzed consecutive TNBC cases treated at AUSL-IRCCS Hospital of Reggio Emilia from 2011 to 2017. 24 Tru-Cut biopsies were selected, comparing 12 patients with pathological complete response (pCR) after neoadjuvant treatment and 12 patients with cancer progression. Then, we performed a morphology-guided transcriptome profiling of the immune infiltrate using our GeoMx-Digital spatial profiler (DSP) to investigate which immune populations were associated with a more favorable outcome. The immune infiltrate of patients showing pCR was significantly enriched for activated Natural Killer (NK) cells, compared to patients with disease progression. Intriguingly, both T-helper CD4- and CD8-T lymphocytes did not reach statistical significance, suggesting a secondary involvement in predicting neoadjuvant efficacy in TNBC patients. We confirmed that NK cells can significantly impair TNBC cell proliferation and viability in vitro and improved the efficacy of chemotherapeutic drugs (paclitaxel, docetaxel). To increase our knowledge of the molecular mechanisms governing NK effector functions toward TNBC, we decided to investigate the specific transcriptional landscape that triggers NK cell activation. We profiled the transcriptome of activated NK cells by RNA-sequencing, identifying several de-regulated pathways involved in NK innate anti-tumor response, including the down-regulation of Immune checkpoint (IC) molecules (CTLA4, CEACAM3, PD1, KIR2DL4, KIR3DX1, KIR3DL3, TIGIT, TIM3, LAG3, etc) and the up-regulation of vesicle-trafficking and autophagy-related proteins (STX5, STX7, BNIP3L, SNAP29, GABARAPL1, RAB4B, etc). To predict upstream transcription regulators, promoters of de-regulated genes were in silico scanned for common binding motifs with the FIMO algorithm, thus identifying a list of candidate Transcription Factors (TFs). Among top-scoring TFs, we identified PAX5 which has been already involved in NK differentiation and cytotoxicity. Other top-scoring TFs are currently under investigation as potential NK Master Regulators of their effector functions, including SMAD3, VEZF1, and MAZ. Overall, our results point out the relevance of NK cells in predicting neoadjuvant treatment response in TNBC patients. Moreover, the modulation of the NK transcriptional program may be a novel tool to potentiate their anti-tumor potential, thus proving novel clues to optimize their application in adoptive cell therapies and in the treatment of TNBC patients. Citation Format: Francesca Reggiani, Benedetta Donati, Moira Ragazzi, Veronica Manicardi, Federica Torricelli, Elisabetta Sauta, Elisa Gasparini, Simonetta Piana, Valentina Sancisi, Alessia Ciarrocchi. Deciphering natural killer transcriptional activation in triple-negative breast cancer: A novel opportunity for adoptive cell therapies? [abstract]. In: Proceedings of the AACR Special Conference: Tumor Immunology and Immunotherapy; 2022 Oct 21-24; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2022;10(12 Suppl) nr A22.

oncology,immunology
Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients

MacLean S Hall,Jamie K Teer,Xiaoqing Yu,Holly Branthoover,Sebastian Snedal,Madeline Rodriguez-Valentin,Luz Nagle,Ellen Scott,Ben Schachner,Patrick Innamarato,Amy M Hall,Jamie Blauvelt,Carolyn J Rich,Allison D Richards,Jake Ceccarelli,T J Langer,Sean J Yoder,Matthew S Beatty,Cheryl A Cox,Jane L Messina,Daniel Abate-Daga,James J Mule,John E Mullinax,Amod A Sarnaik,Shari Pilon-Thomas

DOI: https://doi.org/10.1136/jitc-2023-007288

Abstract:Background: Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) is a promising immunotherapeutic approach for patients with advanced solid tumors. While numerous advances have been made, the contribution of neoantigen-specific CD4+T cells within TIL infusion products remains underexplored and therefore offers a significant opportunity for progress. Methods: We analyzed infused TIL products from metastatic melanoma patients previously treated with ACT for the presence of neoantigen-specific T cells. TILs were enriched on reactivity to neoantigen peptides derived and prioritized from patient sample-directed mutanome analysis. Enriched TILs were further investigated to establish the clonal neoantigen response with respect to function, transcriptomics, and persistence following ACT. Results: We discovered that neoantigen-specific TIL clones were predominantly CD4+ T cells and were present in both therapeutic responders and non-responders. CD4+ TIL demonstrated an effector T cell response with cytotoxicity toward autologous tumor in a major histocompatibility complex class II-dependent manner. These results were validated by paired TCR and single cell RNA sequencing, which elucidated transcriptomic profiles distinct to neoantigen-specific CD4+ TIL. Conclusions: Despite methods which often focus on CD8+T cells, our study supports the importance of prospective identification of neoantigen-specific CD4+ T cells within TIL products as they are a potent source of tumor-specific effectors. We further advocate for the inclusion of neoantigen-specific CD4+ TIL in future ACT protocols as a strategy to improve antitumor immunity.
Abstract 4056: Intratumoral delivery of autologous tumor antigen specific CD4 Th1 cells combined with dendritic cells eradicates HER2 mammary carcinoma

Ganesan Ramamoorthi,Amy Aldrich,Colin Snyder,Brian Czerniecki

DOI: https://doi.org/10.1158/1538-7445.am2023-4056

IF: 11.2

2023-04-04

Cancer Research

Abstract:Abstract Human epidermal growth factor receptor 2 (HER2) overexpression accounts for 30% of invasive breast cancer (BC) and is critically associated with aggressive disease, recurrence and metastasis. Adoptive cell therapy approaches using cytotoxic CD8 T cells and natural killer cells have been shown to trigger anti-tumor immunity in BC. However, the immunosuppressive tumor microenvironment (TME) can inhibit response to these therapies and diminish the presence and function of tumor-infiltrating lymphocytes. Recently, we have shown a critical role for anti-tumor CD4 Th1 cells in dendritic cells (DC) intratumoral (i.t.) delivery in combination with anti-HER2 therapy. This combination therapy enhanced systemic and local anti-tumor immunity and eradicated tumors in HER2 positive BC with a requirement for CD4 Th1 cells. Here we investigated the efficacy of i.t. delivery of both autologous anti-tumor CD4 Th1 cells and tumor antigen pulsed type 1 polarized dendritic cells (HER2-DC1) in a HER2 mammary carcinoma model. CD4 T cells were isolated from BALB/c mice that had completely regressed (pCR) from orthotopic TUBO tumors following HER2-DC1 i.t. or combination therapy with anti-HER2 antibody. CD4 Th1 cells were then expanded by co-culturing with HER2-DC1 in the presence of interleukin (IL)-2 and IL-7 cytokines. BALB/c mice bearing orthotopic TUBO tumors were treated weekly for six weeks with anti-tumor CD4 Th1 cells i.t., non-specific CD4 Th1 cells i.t., HER2-DC1 i.t. or combination therapy. The i.t. delivery of anti-tumor CD4 Th1 cells combined with HER2-DC1 induced a strong anti-tumor response with survival benefit and complete tumor eradication in 50% of treated mice. Importantly, the i.t. delivery of anti-tumor CD4 Th1 cells were critical for providing priming signals to HER2-DC1 within the TME via CD40/CD40L engagement (licensing). This was supported by a strong anti-tumor response and complete tumor regression in 60% of orthotopic TUBO tumor bearing mice treated with CD40/CD40L licensed HER2-DC1 i.t. therapy compared to un-licensed HER2-DC1 i.t. therapy. Additionally, enhanced survival and functionality of human and mouse HER2-DC1 was observed following activation of CD40/CD40L signaling using anti-CD40 agonistic antibody in vitro. Collectively, these results suggest a new promising therapeutic strategy using DC1-anti-tumor CD4 Th1 adoptive cell therapy intratumoral delivery to induce DC1 priming and create robust anti-tumor immunity within the TME in BC. Citation Format: Ganesan Ramamoorthi, Amy Aldrich, Colin Snyder, Brian Czerniecki. Intratumoral delivery of autologous tumor antigen specific CD4 Th1 cells combined with dendritic cells eradicates HER2 mammary carcinoma. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4056.

oncology
Abstract 4106: Non-autonomous enhancement of gPDL1 CAR-T annihilates TNBC development

Chia-Wei Li,Shih-Han Wang,Yun-Ju Lai,Jyun Wang,Chun-Tse Kuo,Shih-Duo Hsu Hung,Shou-Hou Liu

DOI: https://doi.org/10.1158/1538-7445.am2023-4106

IF: 11.2

2023-04-04

Cancer Research

Abstract:Abstract Triple-negative breast cancer (TNBC) is the most aggressive and challenging breast cancer subtype, which does not respond to traditional endocrine and anti-HER2-targeted therapies. PD-L1 is highly enriched in TNBC and has been considered a therapeutic target. Despite the excellent anti-cancer activity, the atezolizumab-based chimeric antigen receptor (CAR) T cells showed a robust off-target effect. In addition, the treatment of solid tumors with CAR-T is limited by abnormal glycosylation in malignant tumors. Targeting glycosylated PD-L1 (gPD-L1) provided tissue specificity against TNBC, implying it can prevent antigen escape and off-target effect. In this study, we generated gPD-L1 CAR-T cells using lentiviral vectors expressing the scFv regions of the anti-gPD-L1 antibody. The gPD-L1 CAR-T cells exhibited antigen-specific activation, cytokine production, and cytolytic activity against TNBCs in vitro and in the xenograft tumors model. CyTOF and single-cell RNA sequencing (scRNA-seq) showed distinct IFNγ-positive cell types. Mechanistically, IFNγ crosstalked with EGFR signaling through Src activation and, in turn, triggered B3GNT3-mediated PD-L1 glycosylation. Inhibition of Src resulted in reduced gPD-L1 expression in TNBC. CRISPR/Cas9 knockout of B3GNT3 in TNBC cells impaired gPD-L1 CAR-T response. As a result of nonautonomous gPDL1 amplification in TNBCs, gPD-L1 CAR-T cells continued to annihilate TNBCs. Additionally, since gPD-L1 CAR-T cells provided higher specificity on TNBC, they had lower normal tissue toxicity. Overall, gPD-L1 CAR-T exhibits excellent anti-tumor activity against TNBCs, and it could be a promising immunotherapy tool to treat TNBCs in clinic. Furthermore, targeting glycosylation moiety on the tumor antigen is a novel approach to lessen CAR-T toxicity in patients. Citation Format: Chia-Wei Li, Shih-Han Wang, Yun-Ju Lai, Jyun Wang, Chun-Tse Kuo, Shih-Duo Hsu Hung, Shou-Hou Liu. Non-autonomous enhancement of gPDL1 CAR-T annihilates TNBC development. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4106.

oncology
Dual immunostimulatory CD73 antibody-polymeric cytotoxic drug complex for triple negative breast cancer therapy

Xiao Xie,Ming Yang,Xue Wei,Hongyu Chu,Weidong Zhao,Na Shen

DOI: https://doi.org/10.1016/j.actbio.2024.09.033

2024-09-26

Abstract:Treatment of triple-negative breast cancer (TNBC) poses significant challenges due to its propensity for metastasis. A key impediment lies in the suppressive immune microenvironment, which fosters tumor progression. This study introduces an approach employing a dual immune-stimulatory CD73 antibody-polymeric cytotoxic drug complex (αCD73-PLG-MMAE). This complex is designed for targeted eradication of TNBC while modulating tumor immunity through mechanisms such as immunogenic cell death (ICD) and interference with the adenosine signaling pathway. By enhancing antitumor immune responses, this strategy offers a highly effective means of treating TNBC and mitigating metastasis. The complex is synthesized by combining αCD73 with poly(L-glutamic acid) (PLG) grafted Fc binding peptides (Fc-III-4C) and Val-Cit-PAB-monomethyl auristatin E (MMAE), exploiting the affinity between αCD73 and Fc-III-4C. αCD73 selectively targets CD73 molecules on both tumor and immune suppressive cells, thereby inhibiting the adenosine pathway. Meanwhile, Val-Cit-PAB-MMAE, activated by cathepsin B, triggers selective release of MMAE, inducing ICD in tumor cells. In a 4T1 tumor model, αCD73-PLG-MMAE significantly enhances drug accumulation in tumors by 4.13-fold compared to IgG-PLG-MMAE, leading to suppression of tumor growth and metastasis. Furthermore, it synergistically augments the antitumor effects of αPD-1, resulting in a tumor inhibition rate of 92 % as compared to 21 % with αPD-1 alone. This study thus presents a pioneering therapeutic strategy for TNBC, emphasizing the potential of targeted immunomodulation in cancer treatment. STATEMENT OF SIGNIFICANCE: Antibody-drug conjugate (ADC) therapy holds promise for treating triple-negative breast cancer (TNBC). However, the current ADC, sacituzumab govitecan, fails to overcome the crucial role of adenosine in the suppressive immune microenvironment characteristic of this "cold tumor". Here, we present a dual immune-stimulatory complex, αCD73-PLG-MMAE, which targets TNBC specifically and modulates tumor immunity through mechanisms such as immunogenic cell death (ICD) and interference with the adenosine signaling pathway. Thus, it kills tumor cells with cytotoxic drugs, comprehensively regulates immunosuppression, and restores a durable immune response. This study proposes an antibody-polymeric drug complex with immunomodulatory and immunoagonist roles, offering new insights into TNBC treatment.
Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes

Parin Shah,Marie-Andrée Forget,Meredith L Frank,Peixin Jiang,Donastas Sakellariou-Thompson,Lorenzo Federico,Roohussaba Khairullah,Chantal Alexia Neutzler,Ignacio Wistuba,Chi-Wan B Chow,Yan Long,Junya Fujimoto,Shiaw-Yih Lin,Anirban Maitra,Marcelo V Negrao,Kyle Gregory Mitchell,Annikka Weissferdt,Ara A Vaporciyan,Tina Cascone,Jack A Roth,Jianjun Zhang,Boris Sepesi,Don L Gibbons,John V Heymach,Cara L Haymaker,Daniel J McGrail,Alexandre Reuben,Chantale Bernatchez

DOI: https://doi.org/10.1136/jitc-2021-003082

IF: 12.469

2022-02-01

Journal for ImmunoTherapy of Cancer

Abstract:Background Adoptive cell transfer (ACT) of tumor-infiltrating lymphocytes (TIL) yielded clinical benefit in patients with checkpoint blockade immunotherapy-refractory non-small cell lung cancer (NSCLC) prompting a renewed interest in TIL-ACT. This preclinical study explores the feasibility of producing a NSCLC TIL product with sufficient numbers and enhanced attributes using an improved culture method. Methods TIL from resected NSCLC tumors were initially cultured using (1) the traditional method using interleukin (IL)-2 alone in 24-well plates (TIL 1.0) or (2) IL-2 in combination with agonistic antibodies against CD3 and 4-1BB (Urelumab) in a G-Rex flask (TIL 3.0). TIL subsequently underwent a rapid expansion protocol (REP) with anti-CD3. Before and after the REP, expanded TIL were phenotyped and the complementarity-determining region 3 β variable region of the T-cell receptor (TCR) was sequenced to assess the T-cell repertoire. Results TIL 3.0 robustly expanded NSCLC TIL while enriching for CD8 + TIL in a shorter manufacturing time when compared with the traditional TIL 1.0 method, achieving a higher success rate and producing 5.3-fold more TIL per successful expansion. The higher proliferative capacity and CD8 content of TIL 3.0 was also observed after the REP. Both steps of expansion did not terminally differentiate/exhaust the TIL but a lesser differentiated population was observed after the first step. TIL initially expanded with the 3.0 method exhibited higher breadth of clonotypes than TIL 1.0 corresponding to a higher repertoire homology with the original tumor, including a higher proportion of the top 10 most prevalent clones from the tumor. TIL 3.0 also retained a higher proportion of putative tumor-specific TCR when compared with TIL 1.0. Numerical expansion of TIL in a REP was found to perturb the clonal hierarchy and lessen the proportion of putative tumor-specific TIL from the TIL 3.0 process. Conclusions We report the feasibility of robustly expanding a T-cell repertoire recapitulating the clonal hierarchy of the T cells in the NSCLC tumor, including a large number of putative tumor-specific TIL clones, using the TIL 3.0 methodology. If scaled up and employed as a sole expansion platform, the robustness and speed of TIL 3.0 may facilitate the testing of TIL-ACT approaches in NSCLC.

oncology,immunology
Tumor-draining lymph nodes are survival niches that support T cell priming against lymphatic transported tumor antigen and effects of immune checkpoint blockade in TNBC

Meghan J. O’Melia,Margaret P. Manspeaker,Susan N. Thomas

DOI: https://doi.org/10.1007/s00262-020-02792-5

2021-01-18

Abstract:Triple negative breast cancer (TNBC) is a significant clinical problem to which immunotherapeutic strategies have been applied with limited success. Using the syngeneic E0771 TNBC mouse model, this work explores the potential for antitumor CD8+ T cell immunity to be primed extratumorally in lymphoid tissues and therapeutically leveraged. CD8+ T cell viability and responses within the tumor microenvironment (TME) were found to be severely impaired, effects coincident with local immunosuppression that is recapitulated in lymphoid tissues in late stage disease. Prior to onset of a locally suppressed immune microenvironment, however, CD8+ T cell priming within lymph nodes (LN) that depended on tumor lymphatic drainage remained intact. These results demonstrate tumor-draining LNs (TdLN) to be lymphoid tissue niches that support the survival and antigenic priming of CD8+ T lymphocytes against lymph-draining antigen. The therapeutic effects of and CD8+ T cells response to immune checkpoint blockade were furthermore improved when directed to LNs within the tumor-draining lymphatic basin. Therefore, TdLNs represent a unique potential tumor immunity reservoir in TNBC for which strategies may be developed to improve the effects of ICB immunotherapy.
Abstract 4027: From tumor progression to therapeutic control: Combinatorial targeting of immune vulnerabilities in TNBC

Amanda Poissonnier,Eivind Valen Egeland,Wesley Horton,Shamilene Sivagnanam,Orian Stapleton,Rossin Erbe,Nell Kirchberger,Konjit Betre,Alyza Skaist,Ludmila Danilova,Andrew Fields,Peter Ordentlich,Andrew C. Adey,Elana J. Fertig,Lisa M. Coussens

DOI: https://doi.org/10.1158/1538-7445.am2024-4027

IF: 11.2

2024-03-23

Cancer Research

Abstract:Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer, associated with limited treatment options and high mortality rates. Although immune checkpoint inhibitors (ICIs) show promise, early clinical results indicate benefits in only a specific subset of patients with TNBC. Preclinical evidence indicates that infiltrating macrophages contribute to breast tumor progression by restricting CD8+ T cell infiltration, activation, and cytotoxicity within tumor microenvironments. Preliminary data has revealed that immune-competent mammary tumor-bearing MMTV-PyMT transgenic mice have slowed tumor progression following sequential combination of a microtubule poison (paclitaxel; PTX) to enhance tumor immunogenicity, plus a macrophage-depleting/reprogramming agent such as a colony-stimulating factor 1 receptor blocking antibody (αCSF1R), and undergo primary tumor regression in 60% of transgenic mice when an ICI targeting PD-1 is applied (3x therapy) by a CD8+ T cell-dependent mechanism. Response to 3x therapy is associated with localized CD8+ T effector and resident memory cell expansion, and increased antigen-specific clonal expansion at primary tumor sites. We hypothesized that epigenetic plasticity was limiting T cell memory and thus impeding long-term tumor control. Using a class 1 benzamide histone deacetylase (HDAC) inhibitor (e.g., entinostat) sequentially added to PTX/αCSF1R/αPD-1 therapy (4x) resulted in primary tumor stasis in 100% of mice, and significantly enhanced overall survival, in two transgenic mouse models of breast cancer (MMTV-PyMT and C3-(1)-TAg). Cohorts were analyzed at distinct time points for primary and metastatic tumor burden, in addition to immunophenotyping (flow cytometry), transcriptional (bulk and scRNA-Seq), epigenetic (sciATAC-Seq), and T cell receptor (TCR) changes correlating with 4x responses. Improved outcome and tumor stasis was associated with increased presence of long-lived central and stem-like memory CD8+ T cell infiltration, intra-tumoral B memory cell, and CD4+ T follicular helper cell infiltration. Tumor stasis was achieved by B and T cell-dependent mechanisms where B cell depletion led to decreased T cell cytotoxicity. Adoptive serum transfer (AST) from 4x-treated MMTV-PyMT mice into either 3x-treated or untreated MMTV-PyMT mice elicited tumor stasis and control. These preclinical studies indicate the complexity of myeloid, B cell and T cell interactions that are co-opted by tumors, and identify novel paths to therapeutic tumor control by targeting vulnerable immune communication programs. Citation Format: Amanda Poissonnier, Eivind Valen Egeland, Wesley Horton, Shamilene Sivagnanam, Orian Stapleton, Rossin Erbe, Nell Kirchberger, Konjit Betre, Alyza Skaist, Ludmila Danilova, Andrew Fields, Peter Ordentlich, Andrew C. Adey, Elana J. Fertig, Lisa M. Coussens. From tumor progression to therapeutic control: Combinatorial targeting of immune vulnerabilities in TNBC [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 4027.

oncology
A Dual-Payload Antibody-Drug Conjugate Targeting CD276/B7-H3 Elicits Cytotoxicity and Immune Activation in Triple-Negative Breast Cancer

Zhuoxin Zhou,Yingnan Si,Jiashuai Zhang,Kai Chen,Ashley George,Seulhee Kim,Lufang Zhou,XXiaoguang Liu

DOI: https://doi.org/10.1158/0008-5472.CAN-23-4099

2024-08-26

Abstract:Triple-negative breast cancer (TNBC) is a highly aggressive and heterogeneous disease that often relapses following treatment with standard radiotherapies and cytotoxic chemotherapies. Combination therapies have potential for treating refractory metastatic TNBC. Here, we aimed to develop an antibody-drug conjugate with dual payloads (DualADC) as a chemo-immunotherapy for TNBC. The overexpression of an immune checkpoint transmembrane CD276 (also known as B7-H3) was associated with angiogenesis, metastasis, and immune tolerance, in over 60% of TNBC patients. Development of a monoclonal antibody (mAb) capable of targeting the extracellular domain of surface CD276 enabled delivery of payloads to tumors, and a platform was established for concurrent conjugation of a traditional cytotoxic payload and an immunoregulating toll-like receptor 7/8 agonist to the CD276 mAb. The DualADC effectively killed multiple TNBC subtypes, significantly enhanced immune functions in the tumor microenvironment, and reduced tumor burden by up to 90-100% in animal studies. Single-cell RNA-sequencing, multiplex cytokine analysis, and histology elucidated the impact of treatment on tumor cells and the immune landscape. This study suggests that the developed DualADC could represent a promising targeted chemo-immunotherapy for TNBC.

Falciparum nomenclature.

OSU-T315 Overcomes Immunosuppression in Triple-Negative Breast Cancer by Targeting the ILK/NF-κB Signaling Pathway to Enhance Immunotherapeutic Efficacy

Abstract P2-04-27: CTLA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer

[The effect of nitric oxide on electroacupuncture analgesia in central nervous system of rats].

Tumor‐infiltrating lymphocyte transfusion in a patient with treatment refractory triple negative breast cancer

Concomitant Expression of CD39, CD69, and CD103 Identifies Antitumor CD8+ T Cells in Breast Cancer Implications for Adoptive Cell Therapy

Augmentation of Antitumour Function of Tumour-infiltrating Lymphocytes Against Triple-negative Breast Cancer by PD-1 Blockade

Enhancing Efficacy of TCR-engineered CD4 + T Cells Via Coexpression of CD8α

Abstract P5-04-28: Targeting TIGIT and PD-1 in triple negative breast cancer

Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells

Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function

Immunotherapy of cancer with 4-1BB

Abstract A22: Deciphering natural killer transcriptional activation in triple-negative breast cancer: A novel opportunity for adoptive cell therapies?

Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients

Abstract 4056: Intratumoral delivery of autologous tumor antigen specific CD4 Th1 cells combined with dendritic cells eradicates HER2 mammary carcinoma

Abstract 4106: Non-autonomous enhancement of gPDL1 CAR-T annihilates TNBC development

Dual immunostimulatory CD73 antibody-polymeric cytotoxic drug complex for triple negative breast cancer therapy

Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes

Tumor-draining lymph nodes are survival niches that support T cell priming against lymphatic transported tumor antigen and effects of immune checkpoint blockade in TNBC

Abstract 4027: From tumor progression to therapeutic control: Combinatorial targeting of immune vulnerabilities in TNBC

A Dual-Payload Antibody-Drug Conjugate Targeting CD276/B7-H3 Elicits Cytotoxicity and Immune Activation in Triple-Negative Breast Cancer